In the United States, delandistrogene moxeparvovec has received approval for the treatment of ambulatory children aged 4 to 5 years with Duchenne muscular dystrophy (DMD) who have a verified mutation in the DMD gene [71]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.